Femasys CE Mark for FemHSG: Small Step, No Change to Binary Risk

What happened

Femasys received CE Mark approval for its FemHSG catheter, expanding its EU fertility care portfolio alongside FemVue. The approval adds a diagnostic tool for in-office fertility evaluation, but the company remains a micro-cap with tiny revenue ($1.48M in 9M-25) and heavy cash burn (~$5M/quarter). With only $4.6M cash and $6.85M convertible notes maturing Nov-25, the going-concern risk dominates. The CE Mark is a positive product line extension but does not solve the urgent financing need or address the binary outcome of the FemBloc pivotal trial. Investors should view this as a marginal step that fails to shift the fundamental risk/reward.

Implication

The CE Mark provides modest commercial optionality but does not alter the dependence on FemBloc results and near-term capital raise. Without a clear path to funding, the stock remains a speculative instrument tied to binary trial outcomes.

Thesis delta

The CE Mark is a positive but minor portfolio expansion in a business that is burning cash at an unsustainable rate. It does not improve the likelihood of FemBloc success or resolve the imminent financing crunch. Our WAIT stance is unchanged; the equity remains a highly speculative option on FemBloc with near-0 fundamental support.